ESO Guideline on covert cerebral small vessel disease

Joanna M. Wardlaw, Stephanie Debette, Hanna Jokinen, Frank Erik De Leeuw, Leonardo Pantoni, Hugues Chabriat, Julie Staals, Fergus Doubal, Salvatore Rudilosso, Sebastian Eppinger, Sabrina Schilling, Raffaele Ornello, Christian Enzinger, Charlotte Cordonnier, Martin Taylor-Rowan, Arne G. Lindgren

Research output: Contribution to journalArticlepeer-review

20 Citations (SciVal)

Abstract

‘Covert’ cerebral small vessel disease (ccSVD) is common on neuroimaging in persons without overt neurological manifestations, and increases the risk of future stroke, cognitive impairment, dependency, and death. These European Stroke Organisation (ESO) guidelines provide evidence-based recommendations to assist with clinical decisions about management of ccSVD, specifically white matter hyperintensities and lacunes, to prevent adverse clinical outcomes. The guidelines were developed according to ESO standard operating procedures and Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. We prioritised the clinical outcomes of stroke, cognitive decline or dementia, dependency, death, mobility and mood disorders, and interventions of blood pressure lowering, antiplatelet drugs, lipid lowering, lifestyle modifications, glucose lowering and conventional treatments for dementia. We systematically reviewed the literature, assessed the evidence, formulated evidence-based recommendations where feasible, and expert consensus statements. We found little direct evidence, mostly of low quality. We recommend patients with ccSVD and hypertension to have their blood pressure well controlled; lower blood pressure targets may reduce ccSVD progression. We do not recommend antiplatelet drugs such as aspirin in ccSVD. We found little evidence on lipid lowering in ccSVD. Smoking cessation is a health priority. We recommend regular exercise which may benefit cognition, and a healthy diet, good sleep habits, avoiding obesity and stress for general health reasons. In ccSVD, we found no evidence for glucose control in the absence of diabetes or for conventional Alzheimer dementia treatments. Randomised controlled trials with clinical endpoints are a priority for ccSVD.

Original languageEnglish
Pages (from-to)CXI-CLXII
JournalEuropean Stroke Journal
Volume6
Issue number2
Early online date2021
DOIs
Publication statusPublished - 2021 Jun 1

Subject classification (UKÄ)

  • Neurology

Keywords

  • cerebral small vessel disease
  • covert
  • dementia
  • lacunes
  • leukoaraiosis
  • outcome
  • prevention
  • recommendations
  • silent brain infarcts
  • stroke
  • White matter hyperintensities

Fingerprint

Dive into the research topics of 'ESO Guideline on covert cerebral small vessel disease'. Together they form a unique fingerprint.

Cite this